Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder

Drug Safety

Volumn 34, Issue 9, 2011, Pages 733-754

  Oefelein, Michael G ^a  

^a ALLERGAN INC   (United States)

Author keywords

Cholinergic receptor antagonists; Darifenacin; Fesoterodine; Muscarinic receptor antagonists; Overactive bladder; Oxybutynin; Solifenacin; Tolterodine; Trospium chloride

Indexed keywords

ACETYLCHOLINE; ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; ANTIULCER AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DARIFENACIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; FESOTERODINE; FLUOXETINE; GALANTAMINE; LONG ACTING DRUG; METFORMIN; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PAROXETINE; PLACEBO; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG;

ABNORMAL VISION; ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; ANTIMUSCARINIC ACTIVITY; BEHAVIOR DISORDER; BINDING AFFINITY; BLOOD BRAIN BARRIER; BLURRED VISION; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID LEVEL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; CONTROLLED DRUG RELEASE; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MONITORING; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG WITHDRAWAL; DYSPEPSIA; EEG ABNORMALITY; HALLUCINATION; HEART DISEASE; HEART VENTRICLE TACHYCARDIA; HUMAN; KIDNEY METABOLISM; LIVER METABOLISM; LOW DRUG DOSE; MEDLINE; NONHUMAN; OVERACTIVE BLADDER; PARASYMPATHETIC FUNCTION; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHARMACOKINETICS; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR AFFINITY; REVIEW; SLEEP DISORDER; SOMNOLENCE; SUSTAINED DRUG RELEASE; TORSADE DES POINTES; URINARY EXCRETION; URINE INCONTINENCE; UROTHELIUM; VERTIGO; XEROSTOMIA;

CHOLINERGIC ANTAGONISTS; CLINICAL TRIALS AS TOPIC; HUMANS; MUSCARINIC ANTAGONISTS; RECEPTORS, MUSCARINIC; URINARY BLADDER, OVERACTIVE;

EID: 80051577809     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11592790-000000000-00000     Document Type: Review

References (160)

1. Wein AJ, Rovner ES.Definition and epidemiology of overactive bladder. Urology 2002 Nov; 60 (5 Suppl. 1): 7-12; discussion, 12 (Pubitemid 36009213)
2. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001 Jun; 87 (9): 760-6 (Pubitemid 34204313)
3. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007 Nov; 100 (5): 987-1006 (Pubitemid 47537675)
4. MacDiarmid SA. Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached? BJU Int 2007 Jun; 99 Suppl. 3: 8-12 (Pubitemid 46608434)
5. Dmochowski RR, Starkman JS, Davila GW. Transdermal drug delivery treatment for overactive bladder. Int Braz J Urol 2006 Sep-Oct; 32 (5): 513-20 (Pubitemid 44794719)
6. Chancellor MB, de Miguel F. Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. Geriatrics 2007 May; 62 (5): 15-24
7. Staskin DR, Zoltan E. Anticholinergics and central nervous system effects: are we confused? Rev Urol 2007; 9 (4): 191-6
8. Waine E, Hashim H, Abrams P. Management of the overactive bladder: a review of pharmacological therapies and methods used by the urological specialist. Can J Urol 2007 Apr; 14 (2): 3478-88
9. Dmochowski R, Staskin DR. The Q-T interval and antimuscarinic drugs. Curr Urol Rep 2005 Nov; 6 (6): 405-9
10. D'Souza AO, Smith MJ, Miller LA, et al. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 2008 Apr; 14 (3): 291-301 (Pubitemid 351711980)
11. Rosenberg MT, Newman DK, Tallman CT, et al. Overactive bladder: recognition requires vigilance for symptoms. Cleve Clin J Med 2007 May; 74 Suppl. 3: S21-9
12. Frohlich G, Burmeister S, Wiedemann A, et al. Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle: a placebo controlled, randomized clinical test. Arzneimittelforschung 1998 May; 48 (5): 486-91 (Pubitemid 28247635)
13. Kim Y, Yoshimura N, Masuda H, et al. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology 2005 Feb; 65 (2): 238-42 (Pubitemid 40248004)
14. Lehtoranta K, Tainio H, Lukkari-Lax E, et al. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scan J Urol Nephrol 2002 Feb; 36 (1): 18-24 (Pubitemid 34225297)
15. Walter P, Grosse J, Bihr AM, et al. Bioavailability of trospium chloride after intravesical instillation in patients with neurogenic lower urinary tract dysfunction: a pilot study. Neurourol Urodyn 1999; 18 (5): 447-53 (Pubitemid 29468396)
16. Kim Y, Yoshimura N, Masuda H, et al. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Int 2006 Feb; 97 (2): 400-3
17. Chuang YC, Thomas CA, Tyagi S, et al. Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct 2008 Oct; 19 (10): 1353-7
18. Riedl CR. The significance of the urine-blood-barrier for urge generation and possible changes in the aging bladder. In: Plas E, Pfluger H, Maier U, et al., editors. The aging bladder. Vienna: Springer, 2003: 75-84
19. Sanctura XR®(trospium chloride extended release): US prescribing information. Irvine (CA): Allergan, Inc., 2008
20. VESIcare®(solifenacin succinate) tablets: US prescribing information. Research Triangle Park (NC): GlaxoSmith-Kline, 2008
21. Enablex®(darifenacin) extended release tablets: US prescribing information. Rockaway (NJ): Warner Chilcott (US), LLC, 2010
22. Ditropan®(oxybutynin chloride) tablets and syrup: US prescribing information. Raritan (NJ): Ortho-McNeil Pharmaceutical, Inc., 2008
23. Ditropan XL®(oxybutynin chloride) extended release tablets: US prescribing information. Raritan (NJ): Ortho-McNeil-Janssen Pharmaceuticals, Inc., 2009
24. Detrol®(tolterodine tartrate tablets): US prescribing information. New York: Pfizer Inc, 2008
25. Detrol®LA (tolterodine tartrate extended release capsules): US prescribing information. New York: Pfizer Inc, 2009
26. Toviaz®(fesoterodine fumarate): US prescribing information. New York: Pfizer Inc, 2010
27. Oxytrol®(oxybutynin transdermal system) patch: US prescribing information. Morristown (NJ): Watson Pharmaceuticals, Inc., 2010
28. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008 Jul; 9 (10): 1787-96
29. Malhotra B, Wood N, Sachse R, et al. Lipophilicity of 5-hydroxymethyl tolterodine, the active metabolite of fesoterodine. 4th International Consultation on Incontinence; 2008 July 5-8; Paris
30. Maniscalco M, Singh-Franco D, Wolowich WR, et al. Solifenacin succinate for the treatment of symptoms of overactive bladder. Clin Ther 2006 Sep; 28 (9): 1247-72 (Pubitemid 44585291)
31. GELNIQUE (oxybutynin chloride) 10% topical gel: US prescribing information. Corona (CA): Watson Pharmaceuticals, Inc., 2009
32. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006 Jul; 148 (5): 565-78 (Pubitemid 43993048)
33. Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 2006 Feb; 147 Suppl. 2: S80-7 (Pubitemid 43237576)
34. Heading CE. YM-905. Curr Opin CPNS Investig Drugs 2000; 2 (3): 321-5
35. Napier C, Gupta P. Darifenacin is selective for the human recombinant M2 receptor subtype [abstract no. 445]. Annual Meeting of the International Continence Society (ICS); 2002 Aug 20; Heidelburg
36. Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 2001; 18 (4): 277-304 (Pubitemid 32391815)
37. Olshansky B, Foote J, Arguinzoniz M, et al. The effects of darifenacin and tolterodine on heart rate (HR) in patients with overactive bladder (OAB) [abstract no. 124]. 36th Annual Meeting of the International Continence Society (ICS); 2006 Aug 10; Christchurch
38. Reiz JL, Salem P, Darke AC. Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin. J Clin Pharmacol 2007 Mar; 47 (3): 351-7 (Pubitemid 46294713)
39. Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 2003; 42 (14): 1243-85 (Pubitemid 37491488)
40. Sathyan G, Dmochowski RR, Appell RA, et al. Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin. Clin Pharmacokinet 2004; 43 (14): 1059-68 (Pubitemid 39602019)
41. McInnes GT, Brodie MJ. Drug interactions that matter: a critical reappraisal. Drugs 1988 Jul; 36 (1): 83-110
42. Preskorn SH, Lacey RL. Polypharmacy: when is it rational? J Psychiatr Pract 2007 Mar; 13 (2): 97-105 (Pubitemid 46588311)
43. Colucci VJ, Rivey MP. Tolterodine-warfarin drug interaction. Ann Pharmacother 1999 Nov; 33 (11): 1173-6
44. Taylor JR. Probable interaction between tolterodine and warfarin. Pharmacotherapy 2006 May; 26 (5): 719-21 (Pubitemid 43673057)
45. Rahimy M, Hallen B, Narang P. Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers. Arzneimittelforschung 2002; 52 (12): 890-5 (Pubitemid 36033186)
46. Wilkinson GR. Drug metabolism and variability among patients in drug response.N Engl J Med 2005 May 26; 352 (21): 2211-21
47. Brynne N, Svanstrom C, Aberg-Wistedt A, et al. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. Br J Clin Pharmacol 1999 Oct; 48 (4): 553-63 (Pubitemid 29454236)
48. Devineni D, Skerjanec A, Woodworth TG. Drug-drug interaction potential of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, with cytochrome P450 (CYP) 2D6 inhibitors and substrates [abstract]. AAPS J 2005; 7 Suppl. 2: M1302
49. Devineni D, Skerjanec A, Woodworth TG. Drug-drug interaction potential of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, with cytochrome P450 (CYP) 3A4 inhibitors and substrates [abstract]. AAPS J 2005; 7 Suppl. 2: M1300
50. Malhotra B, Sachse R, Wood N. Evaluation of drug-drug interactions with fesoterodine. Eur J Clin Pharmacol 2009 Jun; 65 (6): 551-60
51. Sathyan G, Hu W, Chancellor MB, et al. Comparison of CYP3A4 inhibitor effects on the stereoselective pharmacokinetics of extended release oxybutynin and conventional oxybutynin [abstract]. Pharm Sci 1999; 1: 2056
52. Swart PJ, Krauwinkel WJ, Smulders RA, et al. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers. Basic Clin Pharmacol Toxicol 2006 Jul; 99 (1): 33-6 (Pubitemid 44034392)
53. Brynne N, Forslund C, Hallen B, et al. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol 1999 Oct; 48 (4): 564-72 (Pubitemid 29454237)
54. Doroshyenko O, Jetter A, Odenthal KP, et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 2005; 44 (7): 701-20 (Pubitemid 40994080)
55. Sandage B, Sabounjian L, Shipley J, et al. Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin. J Clin Pharmacol 2006 Jul; 46 (7): 776-84 (Pubitemid 43882801)
56. Data on file, Allergan, Inc.
57. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006 Aug; 50 (2): 317-26 (Pubitemid 44038078)
58. Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 2005 Feb; 27 (2): 144-53 (Pubitemid 40462007)
59. Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride is undetectable in the older human central nervous system. J Am Geriatr Soc 2010 Aug; 58 (8): 1618-9
60. Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010 Aug; 64 (9): 1294-300
61. Geyer J, Gavrilova O, Petzinger E. The role of p-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos 2009 Jul; 37 (7): 1371-4
62. Geyer J, Gavrilova O, Schwantes U. Differences in the brain penetration of the anticholinergic drugs trospium chloride and oxybutynin. UroToday Int J 2010 Feb; 3 (1)
63. Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet 2006; 45 (4): 325-50
64. European Medicines Agency. Toviaz: European Public Assessment Report, scientific discussion, 2007 [online]. Available from URL: http://www.ema.europa. eu/humandocs/PDFs/EPAR/toviaz/H-723-en6.pdf [Accessed 2010 July 13]
65. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008 Sep; 54 (3): 543-62
66. Zinner N, Tuttle J, Marks L, et al. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 2005 Sep; 23 (4): 248-52
67. Homma Y, Paick JS, Lee JG, et al. Clinical efficacy and tolerability of extended-release tolterodine and immediaterelease oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial [published erratum appears in BJU Int 2004 May; 93 (7): 1135]. BJU Int 2003 Nov; 92 (7): 741-7 (Pubitemid 37475818)
68. Malone-Lee J, Shaffu B, Anand C, et al. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder-a randomized controlled trial. J Urol 2001 May; 165 (5): 1452-6 (Pubitemid 32410212)
69. Anderson RU, MacDiarmid S, Kell S, et al. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. Int Urogynecol J 2006 Sep; 17 (5): 502-11 (Pubitemid 44138258)
70. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007 Oct; 52 (4): 1204-12 (Pubitemid 47332062)
71. Rackley R, Weiss JP, Rovner ES, et al. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006 Apr; 67 (4): 731-6; discussion, 736
72. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001 Mar; 57 (3): 414-21 (Pubitemid 32192963)
73. Zinner NR, Mattiasson A, Stanton SL, et al. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002 May; 50 (5): 799-807 (Pubitemid 34496674)
74. Roehrborn CG, Abrams P, Rovner ES, et al. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int 2006 May; 97 (5): 1003-6
75. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003 Jun; 78 (6): 687-95 (Pubitemid 36665898)
76. Chu FM, Dmochowski RR, Lama DJ, et al. Extendedrelease formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. Am J Obstetr Gynecol 2005 Jun; 192 (6): 1849-54; discussion, 1854-5
77. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005 Feb; 173 (2): 493-8
78. Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998 Jan; 46 (1): 8-13 (Pubitemid 28037667)
79. Kay GG, Staskin DR, MacDiarmid SA, et al. Do effects of oxybutynin on cognition depend on the route of administration: topical or oral? [abstract no. P15]. Mid-Atlantic Section of the American Urological Association 68th Annual Meeting. Can J Urol 2010; 17 (4): 5316
80. Lackner TE, Wyman JF, McCarthy TC, et al. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc 2008 May; 56 (5): 862-70 (Pubitemid 351652413)
81. Isik AT, Celik T, Bozoglu E, et al. Trospium and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging 2009 Oct; 13 (8): 672-6
82. Jewart RD, Green J, Lu CJ, et al. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry 2005 Apr; 13 (4): 324-8 (Pubitemid 41031080)
83. MacDiarmid SA. Concomitant medications and possible side effects of antimuscarinic agents. Rev Urol 2008 Spring; 10 (2): 92-8
84. Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001; 62 Suppl. 21: 11-4 (Pubitemid 32937572)
85. Tune L, Carr S, Hoag E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. AmJ Psychiatry 1992 Oct; 149 (10): 1393-4
86. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001 Jun; 41 (6): 636-44 (Pubitemid 32493358)
87. Diefenbach K, Donath F, Maurer A, et al. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Invest 2003; 23 (6): 395-404 (Pubitemid 36724158)
88. Diefenbach K, Arold G,Wollny A, et al. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ‡50 years. BJU Int 2005 Feb; 95 (3): 346-9 (Pubitemid 40283121)
89. Diefenbach K, Jaeger K, Wollny A, et al. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype. Sleep Med 2008 Jul; 9 (5): 579-82 (Pubitemid 351837477)
90. Donnellan CA, Fook L, McDonald P, et al. Oxybutynin and cognitive dysfunction. BMJ 1997 Nov 22; 315 (7119): 1363-4
91. Edwards KR, O'Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc 2002 Jun; 50 (6): 1165-6 (Pubitemid 34666332)
92. Layton D, Pearce GL, Shakir SA. Safety profile of tolterodine as used in general practice in England: results of prescriptionevent monitoring. Drug Saf 2001; 24 (9): 703-13 (Pubitemid 32758569)
93. Salvatore S, Serati M, Cardozo L, et al. Cognitive dysfunction with tolterodine use [letter]. Am J Obstetr Gynecol 2007 Aug; 197 (2): e8 (Pubitemid 47198192)
94. Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use.NEngl J Med 2003 Dec 4; 349 (23): 2274-5 (Pubitemid 37485153)
95. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006 Mar 23; 440 (7083): 463-9
96. Malhotra BK, Glue P, Sweeney K, et al. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 2007 Mar; 81 (3): 377-85 (Pubitemid 46364489)
97. Serra DB, Affrime MB, Bedigian MP, et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, amuscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 2005 Sep; 45 (9): 1038-47 (Pubitemid 41192363)
98. Hussain RM, Hartigan-Go K, Thomas SH, et al. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 1996 Jan; 41 (1): 73-5 (Pubitemid 26011405)
99. Breuel HP, Murtz G, Bondy S, et al. Safety and tolerance of trospium chloride in the high dose range. Arzneimittelforschung 1993 Apr; 43 (4): 461-4 (Pubitemid 23112986)
100. Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur Urol 2005 Sep; 48 (3): 483-7 (Pubitemid 41188409)
101. Cardozo L, Castro-Diaz D, Gittelman M, et al. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int Urogynecol J 2006 Sep; 17 (5): 512-9 (Pubitemid 44138259)
102. Cardozo L, Lisec M, Millard R, et al. Randomized, doubleblind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004 Nov; 172 (5 Pt 1): 1919-24 (Pubitemid 39363090)
103. Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005 May; 95 (7): 993-1001 (Pubitemid 40655694)
104. Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo-and tolterodine-controlled phase 2 dose-finding study [published erratum appears in BJU Int 2004 May; 93 (7): 1135]. BJU Int 2004 Jan; 93 (1): 71-7
105. Chapple CR, Van Kerrebroeck PE, Junemann KP, et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int 2008 Jul 21; 102 (9): 1128-32
106. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002 Aug; 168 (2): 580-6 (Pubitemid 34793301)
107. Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005 Sep; 23 (4): 263-70
108. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003 Aug; 62 (2): 237-42 (Pubitemid 36952069)
109. Dmochowski RR, Sand PK, Zinner NR, et al. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 2008 Mar; 71 (3): 449-54 (Pubitemid 351374733)
110. Foote J, Glavind K, Kralidis G, et al. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 2005 Sep; 48 (3): 471-7 (Pubitemid 41188407)
111. Freeman R, Hill S, Millard R, et al. Reduced perception of urgency in treatment of overactive bladder with extendedrelease tolterodine. Obstetr Gynecol 2003 Sep; 102 (3): 605-11 (Pubitemid 37311230)
112. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004 Apr; 45 (4): 420-9; discussion, 429 (Pubitemid 38376197)
113. Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol 2004 Oct; 22 (4): 251-6 (Pubitemid 41406544)
114. Kaplan SA, Roehrborn CG, Dmochowski R, et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006 Aug; 68 (2): 328-32 (Pubitemid 44175507)
115. Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008 May; 71 (5): 839-43
116. Millard RJ, Halaska M. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Curr Med Res Opin 2006 Jan; 22 (1): 41-8 (Pubitemid 43106906)
117. Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007 Dec; 178 (6): 2488-94 (Pubitemid 350052177)
118. Staskin D, Sand P, Zinner N, et al. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. JUrol 2007 Sep; 178 (3 Pt 1): 978-83; discussion, 983-4
119. Staskin DR, Te AE. Short-and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. BJU Int 2006 Jun; 97 (6): 1256-61 (Pubitemid 43907333)
120. Steers W, Corcos J, Foote J, et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist [published erratum appears in BJU Int 2005 Jun; 95 (9): 1385-6]. BJU Int 2005 Mar; 95 (4): 580-6
121. Wagg A, Wyndaele JJ, Sieber P, et al. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006 Mar; 4 (1): 14-24
122. Yamaguchi O, Marui E, Kakizaki H, et al. Randomized, double-blind, placebo-and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int 2007 Sep; 100 (3): 579-87 (Pubitemid 47205477)
123. ZinnerN, Susset J, Gittelman M, et al. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB [published erratum appears in Int J Clin Pract 2006 Jul; 60 (7): 890]. Int J Clin Pract 2006 Jan; 60 (1): 119-26
124. Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol 2009 Apr; 181 (4): 1764-72
125. Armstrong RB, Dmochowski RR, Sand PK, et al. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. Int Urol Nephrol 2007; 39 (4): 1069-77 (Pubitemid 350193596)
126. Armstrong RB, Luber KM, Peters KM. Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. Int Urol Nephrol 2005; 37 (2): 247-52 (Pubitemid 41349185)
127. Sand PK, Miklos J, Ritter H, et al. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int Urogynecol J Pelvic Floor Dysfunct 2004 Jul-Aug; 15 (4): 243-8 (Pubitemid 39149294)
128. MacDiarmid SA, Anderson RU, Armstrong RB, et al. Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies. J Urol 2005 Oct; 174 (4 Pt 1): 1301-5; discussion, 1305 (Pubitemid 41318712)
129. Chapple CR, Fianu-Jonsson A, IndigM, et al. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 2007 Oct; 52 (4): 1195-203 (Pubitemid 47337035)
130. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005 Sep; 48 (3): 464-70 (Pubitemid 41188406)
131. Chapple C, DuBeau C, Ebinger U, et al. Darifenacin treatment of patients ‡65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007 Oct; 23 (10): 2347-58 (Pubitemid 350033436)
132. Sand PK, Johnson II TM, Rovner ES, et al. Trospium chloride once-daily extended-release is efficacious and tolerated in elderly subjects (aged ‡75 years) with overactive bladder syndrome. BJU Int 2011; 107 (4): 612-20
133. Drutz HP, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J 1999; 10 (5): 283-9 (Pubitemid 29465392)
134. Abrams P, Freeman R, Anderstrom C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998 Jun; 81 (6): 801-10 (Pubitemid 28300606)
135. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997 Dec; 50 (6A Suppl.): 90-6; discussion, 97-9
136. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate longterm tolerability and efficacy of trospium chloride in patients with detrusor instability. World JUrol 2003 May; 20 (6): 392-9 (Pubitemid 44175311)
137. Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults [update of Cochrane Database Syst Rev 2002; (3): CD003781]. Cochrane Database Syst Rev 2006; (4): CD003781
138. Corcos J, Casey R, Patrick A, et al. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. BJU Int 2006 Mar; 97 (3): 520-7
139. Chapple C, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005 Jul; 48 (1): 5-26 (Pubitemid 40835585)
140. Hay-Smith J, Herbison P, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005; (3): CD005429
141. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004 Apr; 99 (4): 750-9 (Pubitemid 38612817)
142. Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993 Jul-Aug; 3 (4): 335-48
143. Monane M, Avorn J, Beers MH, et al. Anticholinergic drug use and bowel function in nursing home patients. Arch Intern Med 1993 Mar 8; 153 (5): 633-8 (Pubitemid 23072392)
144. Szonyi G, Collas DM, Ding YY, et al. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 1995 Jul; 24 (4): 287-91
145. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001 Apr; 76 (4): 358-63 (Pubitemid 32248750)
146. Abrams P,Malone-Lee J, Jacquetin B, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001; 18 (7): 551-60 (Pubitemid 32664728)
147. Noe L, Sneeringer R, Patel B, et al. The implications of poor medication persistence with treatment for overactive bladder. Manag Care Interface 2004 Nov; 17 (11): 54-60 (Pubitemid 40444166)
148. Campbell UB, Stang P, Barron R. Survey assessment of continuation of and satisfaction with pharmacological treatment for urinary incontinence. Value Health 2007; 11 (4): 726-32 (Pubitemid 352032811)
149. Appell RA, Abrams P, Drutz HP, et al. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol 2001 Apr; 19 (2): 141-7 (Pubitemid 33777045)
150. Takei M, Homma Y, The Japanese Tolterodine Study, et al. Long-term safety, tolerability and efficacy of extendedrelease tolterodine in the treatment of overactive bladder in Japanese patients. Int J Urol 2005 May; 12 (5): 456-64 (Pubitemid 41015153)
151. Haab F, Cardozo L, Chapple C, et al. Long-term openlabel solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005 Mar; 47 (3): 376-84 (Pubitemid 40248865)
152. Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002 Jun; 41 (6): 588-95 (Pubitemid 35333914)
153. Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 2006 Nov; 98 (5): 1025-32 (Pubitemid 44536453)
154. Hill S, Elhilali M, Millard RJ, et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. Curr Med Res Opin 2007 Nov; 23 (11): 2697-704 (Pubitemid 350146407)
155. Yu YF, Nichol MB, Yu AP, et al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005 Jul-Aug; 8 (4): 495-505 (Pubitemid 41726103)
156. Chui MA, Williamson T, Arciniega J, et al. Patient persistency with medications for overactive bladder [abstract no. PUK11]. Value Health 2004; 7 (3): 366
157. Shaya FT, Blume S, Gu A, et al. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005 Jul; 11 (4 Suppl.): S121-9 (Pubitemid 41022720)
158. Zhou Z, Barr C, Torigoe Y, et al. Persistence of therapy with drugs for overactive bladder [abstract no. PUR3]. Value Health 2001; 4: 162
159. Brostrom S, Hallas J. Persistence of antimuscarinic drug use. Eur J Clin Pharmacol 2009 Mar; 65 (3): 309-14
160. Dmochowski RR, Peters KM, Morrow JD, et al. Randomized, double-blind, placebo-controlled trial of flexibledose fesoterodine in subjects with overactive bladder. Urology 2010 Jan; 75 (1): 62-8